NICE Rejects Lucentis for Diabetic Macular Edema

by Kathy Jones on  March 4, 2011 at 9:09 PM Drug News   - G J E 4
Leading drug maker Novartis received a major blow on Friday after the British health agency revealed that it has rejected the approval for Lucentis for treating Diabetic Macular Oedema (DMO).
 NICE Rejects Lucentis for Diabetic Macular Edema
NICE Rejects Lucentis for Diabetic Macular Edema

Lucentis has been in news for some time due to its heavy price tag with the drug costing over $1,200 for each injection. The drug was discovered by Roche's US biotech firm, Genentech, and has proved to be successful for both Novartis and Roche, with annual sales exceeding $1.5 billion.

Though Lucentis is already available in the British market, with the National Institute for Health and Clinical Excellence (NICE) approving it for wet age-related macular degeneration, the health agency felt that the drug did not provide value for money when treating DMO.

Instead Roche's cancer drug, Avastin, has proven to be as effective in treating DMO and is available at a fraction of Lucentis' price at $50 per injection.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions
Well, the price of the drug is exorbitantly expensive. If there is a drug that is cheaper and has the same effect, then it's better to use the cheaper drug. It's for the benefit of the patients since not all patients can afford this expensive medicine.
ennairam_23 Sunday, March 6, 2011

You May Also Like